- Lentinula edodes (shiitake) contains several distinct active compounds - lentinan, eritadenine, lentinacin - each with its own mechanism.
- Lentinan is a mushroom polysaccharide studied as an immunomodulator; Japan approved it as adjunctive cancer care in 1985.
- Eritadenine acts on liver cholesterol metabolism via COMT inhibition - a different route from statins.
- Only a concentrated, water-based extract delivers the active polysaccharides; powders and alcohol extracts are too weak.
The scientist who recovered a long-known truth
In Japan it is an official medicine; in much of the West, only a food supplement. We are talking about the same Lentinula edodes mushroom (shiitake), whose power has been quietly used in the East for some 3,000 years. For centuries, Eastern wisdom linked mushrooms with health and life, while Western medicine dismissed it as a fairy tale. In 1936, Dr. Kisaku Mori decided to test what really lay behind those "tales." Thousands of studies, collaboration with scientists worldwide, and the book Mushrooms as Health Foods followed. Diabetes, influenza, liver disease, cancer — in each area Lentinula edodes showed effects. Western medicine did not start treating with mushrooms; it only finally began to document it.
Why does one mushroom affect so many different functions?
Such a question can sound suspicious — if something affects everything, it usually means it affects nothing. In the case of Lentinula edodes, the answer lies in its structure: this mushroom contains several distinct, chemically unrelated active compounds, each working through its own biochemical mechanism:
- Lentinan — a mushroom polysaccharide (a beta-1,3/1,6-D-glucan) that acts as an immunomodulator, binding to immune-cell receptors and activating the defence chain. It was approved in Japan in 1985 as an adjunct to oncological treatment.
- Eritadenine — a compound found almost exclusively in Lentinula edodes, which acts on cholesterol metabolism in the liver via COMT inhibition.
- Lentinacin (KS-2) — activates interferon production and shows antiviral effects.
- AHCC (Active Hexose Correlated Compound) — a polysaccharide fraction studied as an immune-support agent alongside vaccination.
This is not one "miracle" compound. It is a mushroom with several independently acting components.
Effect on immunity and significance in oncology
The immunomodulating effect of Lentinula edodes is its most scientifically documented aspect, with hundreds of clinical studies. On the tumour: studied for suppressing cancer-cell proliferation, encouraging apoptosis (natural cell death) and blocking angiogenesis. On immunity: studied for increasing NK (natural killer) cell activity, activating macrophages and T-cells, and stimulating cytokine production (IL-2, IL-12, IFN-γ). Alongside chemotherapy: studied for strengthening chemotherapy's effect, reducing side effects, improving quality of life and lengthening survival. In Japan, mushroom-polysaccharide preparations have been standard adjunctive oncology care since 1985 — not alternative medicine, but standard practice. Always consult your treating doctor first, especially if you take immunosuppressants.
Eritadenine and cholesterol metabolism
This is an aspect rarely discussed but clinically documented. Eritadenine — found almost exclusively in Lentinula edodes — acts via COMT (catechol-O-methyltransferase) inhibition. Its mechanism differs from statins: instead of blocking cholesterol production, it works on cholesterol metabolism in the liver. For prevention, and together with dietary correction, it is studied as a scientifically grounded choice rather than merely "a little help" — though extracts do not replace statins at critical levels. (See more: cholesterol.)
Antiviral and antibacterial properties
Lentinacin (KS-2) activates interferon production — the body's main antiviral defence system — studied against influenza, HSV (herpes simplex) and HIV. Lentinan has shown activity against bacteria and fungal infections in vitro. This is not an antibiotic substitute, but an activated immune system naturally strengthens resistance to seasonal threats.
A mushroom or an extract — these are not the same
The crucial distinction: eating shiitake is not the same as a concentrated, standardised extract. The active polysaccharides dissolve only in water, so only water-based extraction yields the compounds that matter — alcohol extracts and simple mushroom powders are far too weak. For results, a standardised, water-based extract is essential.
Lentinan AXT by Zenius Labs™ is built on concentrated Lentinus edodes (shiitake) polysaccharides combined with Coriolus versicolor and astaxanthin - a standardised, water-based formula delivering the active compounds discussed here.
Lentinan AXT by Zenius Labs™ →Lentinula edodes is the scientific name for shiitake. It differs from ordinary edible mushrooms in having several unique active compounds — lentinan, eritadenine, lentinacin — each working through a different biochemical mechanism. Eastern medicine used it therapeutically for thousands of years before Western science began documenting it.
In Japan this has been standard practice since 1985. Hundreds of clinical studies are examined for lentinan preparations strengthening chemotherapy, reducing side effects and improving quality of life. Consult your treating doctor first, especially if you take immunosuppressants.
Eritadenine, found almost exclusively in Lentinula edodes, acts on cholesterol metabolism in the liver via COMT inhibition — a different mechanism from statins. It is studied as a prevention support alongside dietary change, but does not replace statins at critical levels.
No. The active polysaccharides dissolve only in water, so only a concentrated, water-based extract delivers the compounds that matter. Alcohol extracts and simple mushroom powders are far too weak for a therapeutic effect.
- Brown GD, et al. Dectin-1 mediates the biological effects of beta-glucans. J Exp Med. 2003. PubMed
- Chanput W, et al. β-Glucans are involved in immune-modulation of THP-1 macrophages. Mol Nutr Food Res. 2012. PubMed
- Ren G, et al. Lentinan modulates the intestinal microbiota and enhances antitumor efficacy. Int J Biol Macromol. 2019. PubMed
- Wasser SP, et al. Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl Microbiol Biotechnol. 2002. PubMed
- Israilides C, et al. In vitro cytostatic and immunomodulatory properties of Lentinus edodes. Phytomedicine. 2008. PubMed
- Okamoto T, et al. Lentinan suppresses expression of cytochrome P450 enzymes. Biofactors. 2004. PubMed
- Bisen PS, et al. Lentinus edodes: A Macrofungus with Pharmacological Activities. Curr Med Chem. 2010. BegellHouse
- Ina K, et al. The use of lentinan for treating gastric cancer. Anticancer Agents Med Chem. 2013. PubMed Central
- Zhang Y, et al. Lentinus edodes modulates macrophage activity. Food Chem. 2002. PubMed
- Gordon M, et al. A phase I study of cimetidine and lentinan in patients with advanced malignancies. J Clin Oncol. 2004. PubMed
- Clynes RA, et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000. PubMed
- Modak S, et al. Rituximab therapy of lymphoma is enhanced by orally administered beta-glucans. Leuk Res. 2005. PubMed
- Ogawa K, et al. Enhanced therapeutic effect against liver metastasis of colon cancer with combined use of lentinan and tegafur/uracil. Oncol Rep. 1997. PubMed
- Chihara G, et al. Inhibition of mouse sarcoma 180 by polysaccharides from Lentinus edodes. Nature. 1970. Nature
- Maeda YY, et al. Antitumor activity of polysaccharides. Cancer Res. 1970. Cancer Research
- Chihara G, et al. Fractionation and purification of the polysaccharides with marked antitumor activity from Lentinus edodes. Cancer Res. 1970. Nature
- Chihara G, et al. Inhibition of mouse sarcoma 180 by lentinan. Int J Cancer. 1969. Wiley
- Hamuro J, et al. Macrophage activation by lymphokines in lentinan-treated mice. Int J Immunopharmacol. 1980. PubMed
- Yoshino S, et al. Enhancement of lymphokine-activated killer cell activity by lentinan. Oncology. 2007. PubMed
- Aoki T, et al. Lentinan activates macrophages and NK cells. Jpn J Cancer Res. 2000. PubMed
- Kosaka A, et al. Macrophage activation by combined treatment with cyclophosphamide and lentinan. Jpn J Exp Med. 2009. PubMed
- Takeshita K, et al. Activation of peritoneal macrophages by lentinan. Chem Pharm Bull. 1996. PubMed
- Takeshita K, et al. T-cell activation by lentinan combined with other immunomodulators. Immunopharmacology. 2004. PubMed
- Maeda M, et al. Augmentation of T-lymphocyte function by lentinan. Jpn J Cancer Res. 1978. PubMed
- Hamuro J, et al. NK activity augmentation by lentinan with special reference to immune adherence. Int J Immunopharmacol. 1976. PubMed
- Maeda YY, et al. Antitumor activity and murine NK cell activation by polysaccharides. J Natl Cancer Inst. 1974. PubMed
- Hamuro J, et al. Enhancement of NK activity by lentinan in aged mice. J Immunopharmacol. 1985. PubMed
- Aoki T, et al. Restoration of immune response to lentinan in advanced cancer patients. Cancer Immunol Immunother. 1984. PubMed
- Herr HW, et al. Intravesical interleukin-2 immunotherapy in superficial bladder cancer. J Urol. 1986. PubMed
- Cheung NK, et al. Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol Immunother. 2002. PubMed
- Uno K, et al. Suppression of TH2 responses by lentinan through modulation of IL-4 and IL-5. Int Immunopharmacol. 2000. PubMed
- Wakui A, et al. Lentinan inhibits allergic asthmatic response. Int Arch Allergy Immunol. 2001. PubMed
- Matsuoka H, et al. Lentinan potentiates immunity and prolongs the survival time of some patients. Anticancer Res. 1997. PubMed
- Zhang M, et al. Dietary supplementation of mushroom polysaccharides and survival outcomes. Int Immunopharmacol. 2011. PubMed
- Nakano H, et al. A multi-institutional prospective study on lentinan and survival in gastric cancer. Jpn J Clin Oncol. 1999. PubMed
- Zhang M, et al. Survival outcomes with lentinan supplementation – multicenter review. Int Immunopharmacol. 2011. PubMed
- Taguchi T, et al. Clinical effects of schizophyllan (SPG) on gastric cancer – a randomized study. Biotherapy. 1995. PubMed
- Fujimoto S, et al. Antitumor effect of lentinan combined with mitomycin C. Cancer Treat Rep. 1991. PubMed
- Nakano H, et al. Lentinan and survival in gastric cancer. Jpn J Clin Oncol. 1999. PubMed
- Oba K, et al. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer Immunol Immunother. 2007. PubMed
- Iino Y, et al. Immunochemotherapies versus chemotherapy as adjuvant treatment after curative resection of gastric cancer. Anticancer Res. 1995. PubMed
- Liu J, et al. Lentinan and antitumor immunotherapy: meta-analysis. PLOS ONE. 2017. PubMed Central
- Sakagami H, et al. Prooxidant action of two antioxidants: ascorbic acid and gallic acid. Anticancer Res. 2011. PubMed
- Xu X, et al. Lentinula edodes polysaccharides and their immunostimulatory effects. Int J Biol Macromol. 2014. PubMed
- Oba K, et al. Individual patient based meta-analysis of lentinan in unresectable gastric cancer. Cancer Immunol Immunother. 2009. PubMed
- Sugano N, et al. Anticarcinogenic actions of water-soluble and alcohol-insoluble fractions from shiitake. Cancer Lett. 1982. PubMed
- Zheng R, et al. Lentinan inhibits colorectal carcinoma cell growth. Exp Ther Med. 2013. PubMed
- Yao JY, et al. Lentinan potentiates anti-tumor effect via inhibition of angiogenesis. Food Chem Toxicol. 2018. PubMed Central
- Kimura Y, et al. TS-1 and lentinan combination immunochemotherapy for gastric cancer. Gan To Kagaku Ryoho. 2003. PubMed
- Matsuoka H, et al. Lentinan potentiates immunity – confirmatory study. Anticancer Res. 1997. PubMed
- Ishigami H, et al. Relationship between prolonged survival and changes of serum IAP after lentinan treatment. Nihon Geka. 1992. PubMed
- Gil-Ramírez A, et al. Water-soluble compounds from Lentinula edodes influencing HMG-CoA reductase and cholesterol metabolism. J Agric Food Chem. 2016. PubMed
- Yang H, et al. Lentinus edodes promotes fat removal in hypercholesterolemic mice. Exp Ther Med. 2013. PubMed
- Wang Y et al. Systematic review and meta-analysis on the efficacy and safety of Injectable Lentinan combined with chemotherapy in the treatment of gastric cancer. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2024. PubMed
- Oba K et al. Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer. Anticancer research. 2009. PubMed
- Wang Y et al. Investigation on the efficiency of lentinan for injection combining cisplatin on treating malignant pleural effusion based on systematic review and meta-analysis. Medicine. 2024. PubMed
- Zhang M et al. Mushroom polysaccharide lentinan for treating different types of cancers: A review of 12 years clinical studies in China. Progress in molecular biology and translational science. 2019. PubMed
- Yin X et al. A meta-analysis of lentinan injection combined with chemotherapy in the treatment of nonsmall cell lung cancer. Indian journal of cancer. 2015. PubMed
- Baral B Holistic Evaluation of Shiitake mushrooms (Lentinula edodes): Unraveling Its Medicinal and Therapeutic Potentials. Chemistry & biodiversity. 2025. PubMed
- Ooi SL et al. Modified Rice Bran Arabinoxylan by Lentinus edodes Mycelial Enzyme as an Immunoceutical for Health and Aging-A Comprehensive Literature Review. Molecules (Basel, Switzerland). 2023. PubMed
- Choi JY et al. Dietary supplementation with rice bran fermented with Lentinus edodes increases interferon-γ activity without causing adverse effects: a randomized, double-blind, placebo-controlled, parallel-group study. Nutrition journal. 2014. PubMed
- Gaullier JM et al. Supplementation with a soluble β-glucan exported from Shiitake medicinal mushroom, Lentinus edodes (Berk.) singer mycelium: a crossover, placebo-controlled study in healthy elderly. International journal of medicinal mushrooms. 2011. PubMed
- Lu H et al. TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011. PubMed
- Ooshiro M et al. [Ten cases of advanced gastro-intestinal cancer that required preoperative dosage of PSK]. Gan to kagaku ryoho. Cancer & chemotherapy. 2009. PubMed
- Tanaka H et al. Impact of adjuvant immunochemotherapy using protein-bound polysaccharide-K on overall survival of patients with gastric cancer. Anticancer research. 2012. PubMed
- Maehara Y et al. Postoperative PSK and OK-432 immunochemotherapy for patients with gastric cancer. Cancer chemotherapy and pharmacology. 1993. PubMed
- Ito G et al. Correlation between efficacy of PSK postoperative adjuvant immunochemotherapy for gastric cancer and expression of MHC class I. Experimental and therapeutic medicine. 2012. PubMed
- Standish LJ et al. Trametes versicolor mushroom immune therapy in breast cancer. Journal of the Society for Integrative Oncology. 2008. PubMed
- Eliza WL et al. Efficacy of Yun Zhi (Coriolus versicolor) on survival in cancer patients: systematic review and meta-analysis. Recent patents on inflammation & allergy drug discovery. 2012. PubMed
- He Z et al. Polysaccharide-Peptide from Trametes versicolor: The Potential Medicine for Colorectal Cancer Treatment. Biomedicines. 2022. PubMed
- Chang Y et al. Preclinical and clinical studies of Coriolus versicolor polysaccharopeptide as an immunotherapeutic in China. Discovery medicine. 2017. PubMed
- Ziaja-Sołtys M et al. Exploring the Anticancer Potential of Coriolus versicolor in Breast Cancer: A Review. Current issues in molecular biology. 2025. PubMed
- Park JS et al. Astaxanthin decreased oxidative stress and inflammation and enhanced immune response in humans. Nutrition & metabolism. 2010. PubMed
- Cheng J et al. The Promising Effects of Astaxanthin on Lung Diseases. Advances in nutrition (Bethesda, Md.). 2021. PubMed
- Lee J et al. Anti-Oxidant and Anti-Inflammatory Effects of Astaxanthin on Gastrointestinal Diseases. International journal of molecular sciences. 2022. PubMed
- Wang T et al. Astaxanthin protected against the adverse effects induced by diesel exhaust particulate matter via improving membrane stability and anti-oxidative property. Journal of hazardous materials. 2023. PubMed
- He J et al. Astaxanthin Alleviates Oxidative Stress in Mouse Preantral Follicles and Enhances Follicular Development Through the AMPK Signaling Pathway. International journal of molecular sciences. 2025. PubMed
- Akramiene D et al. Effects of beta-glucans on the immune system. Medicina (Kaunas, Lithuania). 2007. PubMed
- Ross GD et al. Therapeutic intervention with complement and beta-glucan in cancer. Immunopharmacology. 1999. PubMed
- Li B et al. Yeast beta-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway. Journal of immunology (Baltimore, Md. : 1950). 2006. PubMed
- Liu J et al. Combined yeast-derived beta-glucan with anti-tumor monoclonal antibody for cancer immunotherapy. Experimental and molecular pathology. 2009. PubMed
- Xia Y et al. The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. Journal of immunology (Baltimore, Md. : 1950). 1999. PubMed
- Fang J et al. Structure of a β-glucan from Grifola frondosa and its antitumor effect by activating Dectin-1/Syk/NF-κB signaling. Glycoconjugate journal. 2012. PubMed
- Zhang M et al. β-Glucan from Saccharomyces cerevisiae induces SBD-1 production in ovine ruminal epithelial cells via the Dectin-1-Syk-NF-κB signaling pathway. Cellular signalling. 2019. PubMed
- Gringhuis SI et al. Dectin-1 directs T helper cell differentiation by controlling noncanonical NF-kappaB activation through Raf-1 and Syk. Nature immunology. 2009. PubMed
- Jia XM et al. CARD9 mediates Dectin-1-induced ERK activation by linking Ras-GRF1 to H-Ras for antifungal immunity. The Journal of experimental medicine. 2014. PubMed
- Bode K et al. Dectin-1 Binding to Annexins on Apoptotic Cells Induces Peripheral Immune Tolerance via NADPH Oxidase-2. Cell reports. 2019. PubMed
- Zou X et al. Radioprotective effect of edible and medicinal mushrooms against ionizing radiation: Components, potential mechanisms, and applications. Food research international (Ottawa, Ont.). 2025. PubMed
- Dan A et al. Therapeutic Effects of Medicinal Mushrooms on Gastric, Breast, and Colorectal Cancer: A Scoping Review. Cureus. 2023. PubMed
- Abidin MHZ et al. Antiatherogenic Potential of Extracts from the Gray Oyster Medicinal Mushroom, Pleurotus pulmonarius (Agaricomycetes), In Vitro. International journal of medicinal mushrooms. 2018. PubMed
- Zhang X et al. Edible mushroom polysaccharides: Structural characteristics, chemical modification strategies, and structure-activity relationship: A review. International journal of biological macromolecules. 2025. PubMed
- Narayanan S et al. Medicinal Mushroom Supplements in Cancer: A Systematic Review of Clinical Studies. Current oncology reports. 2023. PubMed
- Wang H et al. Efficacy of biological response modifier lentinan with chemotherapy for advanced cancer: a meta-analysis. Cancer medicine. 2017. PubMed
- Oba K et al. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer immunology, immunotherapy : CII. 2007. PubMed
- Cheng SC et al. mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science (New York, N.Y.). 2014. PubMed
- Kidd P Astaxanthin, cell membrane nutrient with diverse clinical benefits and anti-aging potential. Alternative medicine review : a journal of clinical therapeutic. 2011. PubMed